General form of registration statement for all companies including face-amount certificate companies

Note 8 - Net Loss Per Share - Schedule of Reconciliation of Basic and Diluted Income per Share (Details)

v3.24.4
Note 8 - Net Loss Per Share - Schedule of Reconciliation of Basic and Diluted Income per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Jan. 01, 2024
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Net Income (Loss) Attributable to Parent $ (13,500) $ (6,775) $ (2,832) $ (13,483) $ (1,848) $ 18,691 $ (27,552)
Basic weighted average common shares outstanding (in shares)   5,720,009 5,720,009 5,720,009 5,720,009 5,720,009 5,718,926
Diluted weighted average common shares outstanding (in shares)           5,796,956 5,718,926
Basic net loss per share (in dollars per share)   $ (1.22) $ (0.53) $ (2.46) $ (0.42) $ 0.68 $ (4.82)
Diluted net loss per share (in dollars per share)           $ 0.67 $ (4.82)
Pieris Pharmaceuticals, Inc. [Member]              
Net Income (Loss) Attributable to Parent   $ (2,887) $ (10,752) $ (11,369) $ (19,959) $ (24,543) $ (33,277)
Basic weighted average common shares outstanding (in shares)   1,320,000 1,236,000 1,285,000 1,089,000 1,126,000 927,000
Diluted weighted average common shares outstanding (in shares)   1,320,000 1,236,000 1,285,000 1,089,000    
Basic net loss per share (in dollars per share)   $ (2.19) $ (8.7) $ (8.84) $ (18.33) $ (21.8) $ (35.9)
Diluted net loss per share (in dollars per share)   $ (2.19) $ (8.7) $ (8.84) $ (18.33)